SuperworthIQVIA IQV
- Market cap
- $46B
- PE
- 34.7×
- 10y median 34.9×
- Forward PE
- 20.5×
- 10y median 20.6×
- Price to sales
- 2.7×
- EV/EBIT
- 27.3×
- Revenue, 12 months
- $17B
- +8% on a year ago
- Net margin
- 8.1%
- Free cash flow yield
- 4.7%
IQVIA trades at 34.7× trailing earnings, near its ten-year median. Revenue was $17B over the last twelve months, up 8% on a year earlier with a 8% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.7B+5% | $3.9B+4% | $3.7B+2% | $3.8B+2% | $3.9B+4% | $4B+2% | $3.8B+3% | $4B+5% | $4.1B+5% | $4.4B+10% | $4.2B+8% | $4.4B+9% | |
| Cost of revenue | $2.4B+5% | $2.5B+3% | $2.4B+2% | $2.5B+2% | $2.5B+4% | $2.6B+4% | $2.5B+4% | $2.7B+8% | $2.7B+8% | $2.9B+14% | $2.8B+11% | $2.9B+9% |
| Gross profit | $1.3B+6% | $1.4B+4% | $1.3B+3% | $1.3B+3% | $1.4B+5% | $1.4B−1% | $1.3B+0% | $1.3B−0% | $1.4B−0% | $1.4B+4% | $1.4B+4% | $1.4B+9% |
| SG&A | $502M−3% | $556M−5% | $508M−1% | $509M+6% | $522M+4% | $453M−19% | $508M+0% | $509M+0% | $514M−2% | $468M+3% | $502M−1% | $574M+13% |
| $481M+2% | $501M+32% | $506M+7% | $520M−1% | $550M+14% | $626M+25% | $496M−2% | $506M−3% | $553M+1% | $627M+0% | $514M+4% | $506M+0% | |
| Interest expense | $181M+68% | $181M+41% | $166M+18% | $163M−4% | $170M−6% | $171M−6% | $165M−1% | $182M+12% | $189M+11% | $193M+13% | $192M+16% | $197M+8% |
| Pre-tax income | $349M−3% | $373M+36% | $340M−6% | $436M+16% | $349M+0% | $544M+46% | $323M−5% | $323M−26% | $408M+17% | $537M−1% | $328M+2% | $301M−7% |
| $51M−27% | −$102M | $49M−31% | $75M−7% | $65M+28% | $112M | $61M+25% | $56M−25% | $76M+17% | $59M−47% | $59M−3% | $60M+7% | |
| Net income | $303M+7% | $469M+107% | $288M−0% | $363M+22% | $285M−6% | $437M−7% | $249M−14% | $266M−27% | $331M+16% | $514M+18% | $274M+10% | $256M−4% |
| $1.63+9% | $2.54+112% | $1.56+2% | $1.97+24% | $1.55−5% | $2.42−5% | $1.40−10% | $1.54−22% | $1.93+25% | $2.99+24% | $1.61+15% | $1.53−1% | |
| 185.5M−2% | 184.5M−2% | 184.3M−2% | 184.3M−1% | 184.2M−1% | 180.7M−2% | 177.4M−4% | 173.2M−6% | 171.7M−7% | 171.7M−5% | 169.8M−4% | 167.3M−3% |
Gross profit: 58 periods, Q1 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 9 periods, Q4 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 13 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $4.4B | $4.3B to $4.4B | $3.26 | $3.24 to $3.31 | 11 |
| Q4 FY26 | $4.5B | $4.5B to $4.6B | $3.65 | $3.60 to $3.71 | 10 |
| Q1 FY27 | $4.4B | $4.4B to $4.5B | $3.20 | $3.16 to $3.26 | 8 |
| Q2 FY27 | $4.6B | $4.5B to $4.7B | $3.50 | $3.46 to $3.57 | 8 |
| Q3 FY27 | $4.6B | $4.6B to $4.7B | $3.64 | $3.59 to $3.71 | 8 |
| Q4 FY27 | $4.8B | $4.8B to $4.9B | $4.06 | $4.01 to $4.14 | 8 |
| Q1 FY28 | $4.7B | $4.6B to $4.7B | $3.58 | $3.53 to $3.64 | 9 |
| Q2 FY28 | $4.9B | $4.8B to $4.9B | $3.96 | $3.91 to $4.03 | 9 |
Peers
Companies in Medical - Diagnostics & Research nearest IQVIA's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| Peer median | $37.1B | 39.3× | 34.3× | 29.2× | 6.7× | +8% | 16.8% |
Investors who own it
Investors we follow who held IQVIA at the end of Jun 30, 2026, from their 13F filings.
- Bill NygrenHarris Associates (Oakmark)3.1% of portfolioadded
- Tom GaynerMarkel Group0.1% of portfolio
More on IQVIA
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 28Diagnostics and research stocks with the highest free cash flow yield
- #3of 15Diagnostics and research stocks cheapest against their own PE history
- #7of 20Diagnostics and research stocks with the lowest PE ratio
- #9of 25Diagnostics and research stocks with the lowest EV/EBIT
- #8of 17Diagnostics and research stocks with the fastest earnings growth
- #8of 11Diagnostics and research stocks with the fastest expected revenue growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .